Last reviewed · How we verify
Doptelet (AVATROMBOPAG)
Doptelet works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow.
Doptelet (Avatrombopag) is a small molecule drug developed by Akarx Inc, targeting the thrombopoietin receptor. It was FDA-approved in 2018 for the treatment of thrombocytopenic disorders. Doptelet is a patented medication with no generic manufacturers available. Key safety considerations include its potential to cause bone marrow suppression and thrombocytosis. As a thrombopoietin receptor agonist, Doptelet works by stimulating platelet production in the bone marrow.
At a glance
| Generic name | AVATROMBOPAG |
|---|---|
| Sponsor | Akarx Inc |
| Target | Thrombopoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2018 |
Mechanism of action
Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.
Approved indications
- Thrombocytopenic disorder
Common side effects
- pyrexia
- abdominal pain
- nausea
- headache
- fatigue
- edema peripheral
- headache
- fatigue
- contusion
- epistaxis
Key clinical trials
- Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (PHASE2)
- Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months (PHASE3)
- Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP (PHASE3)
- Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia (PHASE2,PHASE3)
- The Holistic Study (PHASE3)
- Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study (PHASE4)
- An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doptelet CI brief — competitive landscape report
- Doptelet updates RSS · CI watch RSS
- Akarx Inc portfolio CI